Dr. Harrison is an internationally acknowledged specialist in the design of human clinical outcome measurement in Alzheimer’s disease and other cognitive impairments. Dr. Harrison has successfully integrated cognitive testing into drug development programs for many pharmaceutical and biotechnology companies, including eight of the current ‘Fortune’ top 10 pharmaceutical companies. He is an Honorary Senior Lecturer in the Department of Medicine at Imperial College in London, focusing on investigating cognitive change that may show disease progression in Alzheimer’s and other related indications. Dr. Harrison is a member of the American Psychological Association, holds Chartered Psychologist status with the British Psychological Society, and Chartered Scientist status with the UK Science Council. He has authored/co-authored more than 60 books and scientific articles. He has been invited as a specialist for cognitive tests at many international meetings, including the European Task Force for Alzheimer’s Disease and American Alzheimer’s Association roundtable events. Dr. Harrison’s background includes prior positions as Head of Neuropsychology at CeNeS Pharmaceuticals, Principal Consultant at CPC Pharma Services, and Principal Scientist at CogState Ltd. In addition to his current academic appointment, he is a principal consultant at Metis Cognition Ltd and holds a PhD in neuroscience from the University of London.